Therapix Biosciences Stock (NASDAQ: TRPX) - Investor Dashboard


➔ Therapix Biosciences
NASDAQ: TRPX
 TASE: TRPX
Sector: Healthcare
Industry: Pharmaceutical
Country: Israel
Employees:  8
Established: 2005
CEO: Dr. Elran Haber

Summary

Fiscal Year-End: December
Exchange: NASDAQ
Sector: Healthcare
Industry:  Biotech
Auditor:  Ernst & Young
Headquarters: Tel Aviv, Israel

Financials (09/30 pro forma)

Cash on hand: $14.3mm
Fixed Investment: $13K
Shareholders’ Equity: $14.0mm
Revenues – Last Quarter: $0
Adj. Gross Margin : na
EPS : -$0.05

Capital Structure (03/22/17)

Last Financing: 2.3mm Shares at $6.00
Basic Shares: 3.497mm
Warrants: 161K
Options: 135K
Diluted Shares: 3.793mm

Company Brief

Therapix Biosciences (NASDAQ: TRPX) is an Israel-headquartered emerging specialty pharmaceutical company developing unique Cannabinoid technologies in treatment of central nervous system (CNS) disorders.

Therapix is engaged in two drug development programs based on repurposing an FDA, approved synthetic cannabinoid (dronabinol). Therapix has filed for Orphan Drug Designation of its Joint Pharma formulation for TS, which provides for a seven-year exclusive marketing period in the United States.

Therapix also intends to pursue Orphan Drug Designation in Europe. The company priced its NASDAQ IPO at $6 per share on March 22nd (Prospectus).

Repurposing FDA Approved Cannabinoids


Cannabinoid Market Landscape

GW Pharmaceuticals
Market Cap ~3.2B USD:
(GWPH) Sativex sublingual spray for MS spasticity; Epidiolex sublingual spray (botanical CBD) for Epilepsy. (26.1mm shares at $121.17 as of 3/24/17)

INSYS Therapeutics
Market Cap ~761M USD:
(INSY) Syndros synthetic THC oral solution for CINV, anorexia in AIDs patients; Synthetic CBD oral solution for Epilepsy. (71.77mm shares at $10.61 as of 3/24/17)

Zynerba Pharmaceuticals
Market Cap ~259M USD:
(ZYNE) Developing transdermal synthetic gel cannabinoid treatments. (13.2mm shares at $19.65 as of 3/24/17)

Therapix Biosciences
Market Cap ~31M USD:
(TRPX) Repurposing FDA Approved Cannabinoids For New Indications. (3.5mm shares at $8.94 as of 3/24/17)


Highlights

  • Lead candidate (Phase 2) combines THC and PEA to treat Tourette Syndrome
  • Long-term candidate uses ultra-low-dose of THC for Mild Cognitive Impairment
  • MOU with Rafa Laboratories
  • Cash to fund trials following IPO

Growth Strategy

  • Focusing on Central Nervous System
  • Repurposing FDA approved drugs
  • Employing novel delivery technologies
  • Pursuing Orphan Drug designation for Tourette Syndrome

Differentiators

  • Pursuing less expensive, lower risk Section 505(b)(2) regulatory pathway
  • Multiple programs
  • Licensed Yissum’s nasal drug delivery IP
  • Well capitalized

Curated Stories & News


Visit Therapix Biosciences, Ltd.
at www.therapixbio.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Therapix Biosciences, Ltd., is a client of NCV Media, LLC. Read our full disclaimer.

Latest News
Get The App

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.


ncv-news-ios-app-store

ncv-news-google-play

NCV Media, LLC

Thank you for reading

New Cannabis Ventures

Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors.

FOLLOW US ON